P347 Patient perception towards faecal microbiota transplantation for treatment of Inflammatory Bowel Disease
N. Quraishi1, M. McMillan1, M. Widlak*1, L. Nell1, K. Quraishi2, S. Pathmakanthan1, N. Sharma2, T. Iqbal1
1University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Gastroenterology, Birmingham, United Kingdom, 2Heart of England NHS Foundation Trust, Heartlands Hospital, Gastroenterology, Birmingham, United Kingdom
Faecal Microbiota Transplant (FMT) is a novel highly effective treatment for Clostridium difficile infection
(CDI). Initial clinical trials and case reports suggest that this may be a promising therapy for patients with inflammatory bowel disease (IBD). As part of a patient audit regarding our FMT treatment for CDI we performed a survey to evaluate patient attitudes to potentially receiving FMT as treatment for IBD and gauged attitudes towards participation in a future clinical trial evaluating the effectiveness of FMT in IBD.
We conducted a structured survey on patients attending gastroenterology clinics to assess perceptions of effectiveness, tolerability, safety and thresholds for considering FMT as a treatment.
We collected 105 responses (M:F 46:59, Median age 36 years) including 80 (76%) from patients with IBD. 91%
(96/105) felt that this treatment would be effective and 56% (59/105) did not consider it unpleasant. 96% (101/105) patients perceived it to be safe. 72% (76/105) and 82% (86/105) would be comfortable with having FMT via an NG tube or rectal enema route respectively. 78% (82/105) did not have any concerns regarding the faecal transplant being obtained from a screened unrelated donor. 74% (78/105) of the patients would be willing to have FMT as a first line treatment of CDI. 50% (40/80) of IBD patients surveyed would consider FMT as a first line treatment of their IBD, 85% (68/80) if steroid resistant or dependant, 89% (71/80) if failing on biologics and 94% (75/80) as a salvage treatment option prior to surgery. Importantly 75% (60/80) would consider taking part in a clinical trial evaluating faecal microbiota transplantation for treatment of their IBD.
In this survey of patient attitudes to FMT amongst patients from the UK, we found that patients perceived FMT as a potentially effective, safe, tolerable treatment and were inclined to consider this as part of conventional medical therapy for IBD. In our cohort we did not discover reluctance to take part in a trial of FMT for treatment of IBD.